Citigroup
SABS icon

Citigroup’s SAB Biotherapeutics SABS Stock Holding History

Citigroup’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Sell
26,584
-10,221
-28% -$38K ﹤0.01% 4667
2026
Q1 		$141K Buy
36,805
+6,831
+23% +$27.2K ﹤0.01% 4153
2025
Q4 		$112K Buy
29,974
+29,142
+3,503% +$95.9K ﹤0.01% 4270
2025
Q3 		$1.67K Buy
+832
New +$1.88K ﹤0.01% 5524
2022
Q4 		– Sell
-49
Closed – – 5932
2022
Q3 		$0 Sell
49
-15
-23% -$149 ﹤0.01% 6259
2022
Q2 		$1K Sell
64
-638
-91% -$13.4K ﹤0.01% 6083
2022
Q1 		$26K Buy
702
+573
+444% +$26.5K ﹤0.01% 5028
2021
Q4 		$10K Buy
+129
New +$12.1K ﹤0.01% 5563

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup's SABS Position: Q2 2026 in Review

Citigroup reduced its SAB Biotherapeutics (SABS) stake by 28% in Q2 2026, selling an estimated $38K and leaving 26,584 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4667.

Citigroup first reported a position in SABS in Q4 2021 and has held it in 8 quarters since. The position peaked at $141K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Citigroup held 26,584 shares of SAB Biotherapeutics worth $104K as of Q2 2026.
  • Citigroup sold 10,221 SAB Biotherapeutics shares in Q2 2026, an estimated $38K.
  • SAB Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4667 holding.
  • Citigroup first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 8 quarters since.
  • Citigroup's SAB Biotherapeutics position peaked at $141K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.